If you don't see your institution, add your dataset to the main dataverse named "RepOD".
Select the dataverse to which you want to add the new dataset:
You need to Sign In/Sign Up to add a dataset.
Share this dataset on your favorite social media networks.
Kucińska, Małgorzata, 2024, "The combination therapy using tyrosine kinase receptors inhibitors and repurposed drugs to target patient-derived glioblastoma stem cells", https://doi.org/10.18150/NNFQCJ, RepOD, V1
Learn about Data Citation Standards.
The lesson from many studies investigating the efficacy of targeted therapy in glioblastoma (GBM) showed that a future perspective should be focused on combining multiple target treatments. Our research aimed to assess the efficacy of drug combinations against glioblastoma stem cells (GSCs). Patient-derived cells U3042, U3009, and U3039 were obtained from the Human Glioblastoma Cell Culture resource. Additionally, the study was conducted on a GBM commercial U251 cell line. Gene expression analysis related to receptor tyrosine kinases (RTKs), stem cell markers and genes associated with significant molecular targets was performed, and selected proteins encoded by these genes were assessed using the immunofluorescence and flow cytometry methods. The cytotoxicity studies were preceded by analyzing the expression of specific proteins that serve as targets for selected drugs. The cytotoxicity study using the MTS assay was conducted to evaluate the effects of selected drugs/candidates in monotherapy and combinations. The most cytotoxic compounds for U3042 cells were Disulfiram combined with Copper gluconate (DSF/Cu), Dacomitinib, and Foretinib with IC50 values of 52.37 nM, 4.38 µM, and 4.54 µM after 24 h incubation, respectively. Interactions were assessed using SynergyFinder Plus software. The analysis enabled the identification of the most effective drug combinations against patient-derived GSCs. Our findings indicate that the most promising drug combinations are Dacomitinib and Foretinib, Dacomitinib and DSF/Cu, and Foretinib and AZD3759. Since most tested combinations have not been previously examined against glioblastoma stem-like cells, these results can shed new light on designing the therapeutic approach to target the GSC population.
Cancer stem cells, Drug combinations, Drug repurposing, Glioblastoma, Synergy, Tyrosine kinase receptors
Kucinska Malgorzata, Julia Pospieszna, Jing Tang, Natalia Lisiak, Ewa Toton, Blazej Rubis, Marek Murias, The combination therapy using tyrosine kinase receptors inhibitors and repurposed drugs to target patient-derived glioblastoma stem cells, Biomedicine & Pharmacotherapy, Volume 176, 2024, 116892, ISSN 0753-3322, https://doi.org/10.1016/j.biopha.2024.116892 https://doi.org/10.1016/j.biopha.2024.116892 doi: 10.1016/j.biopha.2024.116892
CC BY - Creative Commons Attribution 4.0
Please select a file or files to be deleted.
The file(s) will be deleted after you click on the Delete button.
Files will not be removed from previously published versions of the dataset.
Please select a file or files to be edited.
For selected file(s) set a license to
Please select a file or files to be downloaded.
Please select a file or files for access request.
Please select restricted file(s) to be unrestricted.
You need to Log In/Sign Up to request access to this file.
Please confirm and/or complete the information needed below in order to continue.
Asterisks indicate required fields
Access to file(s) subject to additional consent under following conditions:
The restricted file(s) selected may not be downloaded because you have not been granted access.
Click Continue to download the files you have access to download.
Are you sure you want to delete this dataset and all of its files? You cannot undelete this dataset.
Are you sure you want to lift the embargo?
Once you lift the embargo, you will not be able to set it again.
Are you sure you want to delete this draft version? Files will be reverted to the most recently published version. You cannot undelete this draft.
Use a Private URL to allow those without Dataverse accounts to access your dataset. For more information about the Private URL feature, please refer to the User Guide.
Private URL has not been created.
Are you sure you want to disable the Private URL? If you have shared the Private URL with others they will no longer be able to use it to access your dataset.
You will not be able to make changes to this dataset while it is in review.
This dataset cannot be published until Poznan University of Medical Sciences is published. Would you like to publish both right now?
Once you publish this dataset it must remain published.
Are you sure you want to republish this dataset?
Select if this is a minor or major version update.
This dataset cannot be published until Poznan University of Medical Sciences is published by its administrator.
This dataset cannot be published until Poznan University of Medical Sciences and RepOD are published.
Are you sure you want to deaccession? The selected version(s) will no longer be viewable by the public.
Contact person for this dataset, having substantive knowledge of the data
Please fill this out to prove you are not a robot.
